MYADML: A Protein Involved in Myeloid Differentiation and Cancer Development

Target Name: MYADML

NCBI ID: G151325

MYADML

Other Name(s): myeloid associated differentiation marker like (pseudogene) | Myeloid associated differentiation marker like (pseudogene)

MYADML: A Protein Involved in Myeloid Differentiation and Cancer Development

Myeloid-associated differentiation marker-like (MYADML) is a protein that is expressed in the myeloid cells of the bone marrow. It is a key regulator of myeloid differentiation and has been implicated in the development and progression of many diseases, including cancer. Despite its importance, little is known about MYADML and its potential as a drug target or biomarker. In this article, we will explore the biology and potential clinical applications of MYADML.

TheMYADML gene

MYADML is a single-copy gene located on chromosome 11q22. It is a member of the myeloid-associated differentiation gene family (MADGF) and is expressed in the myeloid cells of the bone marrow.MYADML is a 21-kDa protein that consists of 105 amino acid residues. It has a characteristic N-terminal extracellular domain that is involved in its stability and functions as a scaffold.

MYADML functions as a regulator of myeloid differentiation

MYADML is involved in the regulation of myeloid differentiation by controlling the levels of different cell surface markers in the myeloid cells. It does this by regulating the activity of the transcription factor, Myeloid-derived suppressor (MDS), which is responsible for suppressing the myeloid differentiate

Protein Name: Myeloid Associated Differentiation Marker Like (pseudogene)

The "MYADML Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYADML comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets